News Letter 2008

An Organization Dedicated to Prevention of Infectious Diseases and promoting public awareness and Education about immunization and vaccine-preventable diseases in Developing Countries

Organization: JN is a global research-based company that develops and markets products to protect from Malaria, TB, HIV and Bacterial meningitis  diseases in more than 30 developing countries since 1998. Now, JN is a leading innovation-driven Biopharmaceutical corporation. JN stands 3rd in the World developed NmVac4-A/C/Y/W135™  (Meningococcal meningitis groups A, C, Y, W-135) polysaccharide vaccine for adults  & children and stands 2nd in the World in providing NmVac4-A/C/Y/W135 DT™ (Meningitis A, C, Y, W-135 Diphtheria conjugate) meningococcal vaccine for all ages.  JN is a partner of Global Health Organization such as Clinton Global Initiative, and GBC. JN also partnering with  several other non-profit global health organizations, NGOs, local governments and communities in developing countries to address the health issues related to HIV/AIDS, Malaria, Tuberculosis and Bacterial Meningitis by underserved communities in West Africa, South East Asia and Latin Americas.

Our Presence: The Corporation opened its first overseas branch in 2005 in Abidjan, Côte d'Ivoire and later in 2006 in Ouagadougou, Burkina Faso. This year (2008) first South East Asia branch opened in Malaysia. Operating in Africa and Asia enables the company to more efficiently distribute many of its products to resource-poor communities.